Innate Pharma (IPH)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 1.266 |
|---|---|
| 52-week range | 1.030 – 2.330 |
| Return, 1 month / 3 months | −19.9% / −19.0% |
| Return, 1 year / 3 years | −30.0% / −44.2% |
| Trend | Below its 200-day average |
| RSI (14) | 31 |
| Volatility (1 year) | 66.6% |
| Worst drawdown (1 year) | -44.1% |
| Average daily value traded | 0.83M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It designs and develops therapeutic antibodies and antibody-drug conjugates that harness the body's immune system, with a focus on natural killer cells and other innate immune pathways. Its pipeline targets cancer and inflammatory conditions, and the company works with pharmaceutical partners on several programmes. Innate Pharma's activities span preclinical research through clinical development, and its medicines are intended for patients with serious diseases such as blood cancers and solid tumours.
Innate Pharma trades under the code IPH on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Innate Pharma (IPH) trades on the Euronext Paris in France. It last closed at EUR 1.266 on 19 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 346 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 30.0% and over the last three months it fell 19.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.0% | ||
| From 52-week high | -42.2% | ||
| Momentum | 50 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -19.0% | ||
| 6-month return | 9.7% | ||
| 12-month return, skipping the last month | -12.6% | ||
| Risk (lower is better) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 66.6% | ||
| Worst drawdown (1 year) | -44.1% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 0.83M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
Returns
| 1 week | −1.2% |
|---|---|
| 1 month | −19.9% |
| 3 months | −19.0% |
| 6 months | +9.7% |
| 1 year | −30.0% |
| 3 years | −44.2% |
| 5 years | −72.8% |
Signals
| 50-day / 200-day average | 1.603 / 1.489 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.059 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.